中源协和：全资子公司VUM02注射液临床试验申请获受理

Core Points - Zhongyuan Union (600645.SH) announced that its wholly-owned subsidiary, Wuhan Guanggu Zhongyuan Pharmaceutical Co., Ltd., received the acceptance notice for the clinical trial application of VUM02 injection from the National Medical Products Administration on August 1, 2025 [2] - VUM02 injection is a self-developed cryopreserved cell preparation by Zhongyuan Union, aimed at treating post-pneumonia pulmonary fibrosis [2] Company Summary - The company is advancing its research and development efforts with the VUM02 injection, indicating a focus on innovative treatments in the pharmaceutical sector [2] - The approval for clinical trials represents a significant milestone for the company, potentially enhancing its product pipeline and market position [2]